Sponsor or institution
Clinical trials and research at Institute of Hematology & Blood Diseases Hospital, China
As of November 12, 2026, Find a Trial lists 150 clinical trials run by Institute of Hematology & Blood Diseases Hospital, China that are recruiting, at sites in 2 countries (most in China (150), Hong Kong (4)). 1 was first registered in the last 30 days. By phase: Phase 2 (66), Phase 1/2 (14), Phase 1 (13), Early Phase 1 (8). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 150Clinical trials
- 1New in 30 days
- 2Countries
Newest trials
All recruiting trials (150)
-
QLS4131 plus isatuximab for newly diagnosed primary plasma cell leukemia
This trial tests whether a BCMA/GPRC5D/CD3 trispecific antibody (QLS4131) added to isatuximab can help adults with newly diagnosed primary plasma cell leukemia see better treatment responses.
-
F182112 in relapsed/refractory autoimmune hemolytic anemia
A small early study tests F182112 as a single treatment for adults with AIHA that has not responded to other therapies, to see if it’s safe and what dose works best.
-
Multi-target drugs sequentially combine therapy in adults with newly diagnosed immune thrombocytopenia
This study tests whether starting with standard steroids plus a TPO-RA, then adding a second targeted therapy if needed, can improve platelet counts in adults with newly diagnosed ITP.
-
Isatuximab in adults with refractory severe aplastic anemia
This study tests whether the drug isatuximab can help adults with refractory severe aplastic anemia who have very low blood counts.
-
Zeprumetostat in relapsed/refractory T-cell large granular lymphocytic leukemia
This study tests whether taking Zeprumetostat by mouth can help people with relapsed or hard-to-treat T-cell large granular lymphocytic leukemia.
-
CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia
A new combination therapy using CM336 with isatuximab, lenalidomide, and bortezomib is being tested in adults newly diagnosed with primary plasma cell leukemia to see if it can improve treatment responses and safety.
-
R-PMDT Regimen for Newly Diagnosed PCNSL
This study tests the R-PMDT treatment approach in people newly diagnosed with primary CNS lymphoma to see how many respond.
-
CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment
This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.
-
Brain network changes in adults with anemia measured by fNIRS
This project will use functional near-infrared spectroscopy (fNIRS) to see if brain network connections are altered in adults aged 18–65 who have anemia.
-
Mosunetuzumab and Zeprumetostat in Follicular Lymphoma
This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.
-
Azacitidine plus venetoclax maintenance vs azacitidine alone in AML
This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.
-
Pediatric-style chemotherapy with venetoclax and immunotherapy for adults with Ph-negative acute lymphoblastic leukemia
This treatment plan tests whether pediatric-style chemotherapy combined with venetoclax and optional immunotherapy helps people aged 14–60 with newly diagnosed Ph-negative ALL achieve remission and clear minimal residual disease.
-
Low-intensity chemotherapy with olverembatinib, venetoclax and blinatumomab for newly diagnosed Philadelphia chromosome–positive ALL
This trial will test whether adding venetoclax to a low‑intensity chemotherapy plan together with continuous olverembatinib and planned blinatumomab helps people aged 14+ with newly diagnosed Ph+ ALL get deeper early molecular remission and live longer.
-
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
This trial tests a new induction combo (VAM) to see if it is safe and shows early signs of helping people with newly diagnosed AML who can receive intensive chemotherapy.
-
Zoledronic acid treatment for adults with congenital dyserythropoietic anemia
This trial will try a single intravenous dose of zoledronic acid in adults with congenital dyserythropoietic anemia to see if it raises hemoglobin and reduces the need for blood transfusions.
-
Adverse effects of ATG/ALG treatment in aplastic anemia
This project will see what side effects people with aplastic anemia experience when they receive ATG or ALG therapy.
-
ABL‑ or JAK‑targeted drugs with chemotherapy and venetoclax for Ph‑like ALL
This protocol tests whether adding an ABL‑targeted or JAK‑targeted drug plus venetoclax to standard chemotherapy helps people aged 14–60 with newly diagnosed Ph‑like acute lymphoblastic leukemia get deeper remissions.
-
Orelabrutinib for adults with early-stage untreated marginal zone lymphoma
This trial will try orelabrutinib, a selective oral BTK inhibitor, as first-line treatment for adults with stage I–II marginal zone lymphoma to see if it works and is safe.
-
MRD-guided BCMA/CD3 bispecific antibody after stem cell transplant in newly diagnosed myeloma
This study tests whether adding the BCMA/CD3 bispecific antibody CM336 after autologous stem cell transplant helps patients with newly diagnosed multiple myeloma who still have minimal residual disease.
-
PCC treatment for hemophilia A patients with inhibitors
This trial tests whether giving prothrombin complex concentrate (PCC) during bleeding episodes can stop bleeds in people aged 12–65 with hemophilia A who have inhibitors.
-
Linking autonomic nervous system function to acute graft-versus-host disease
This study tests whether monitoring autonomic nervous system (ANS) function can help detect acute graft-versus-host disease early in patients receiving HLA-haploidentical transplants.
-
Daratumumab versus rituximab for children with primary immune thrombocytopenia
This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.
-
Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia
This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.
-
Liposomal amphotericin B (AmBisome) for breakthrough invasive fungal infections in children and teens with blood cancers
This project will see if liposomal amphotericin B (AmBisome) works and is safe for treating breakthrough invasive fungal infections in children and adolescents with hematological malignancies who were taking triazole or echinocandin prevention.
-
IASO206 injection for relapsed or refractory multiple myeloma
A single-arm early study is testing IASO206 injection to see if it is safe and tolerable for adults with relapsed or refractory multiple myeloma who have tried at least two prior therapies.
-
Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases
This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.
-
Chidamide maintenance after stem cell transplant for intermediate- or high-risk AML
This trial tests whether taking oral chidamide after an allogeneic stem cell transplant helps adults with intermediate- or high-risk AML stay in remission and live longer.
-
Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma
This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.
-
Sulforaphane to speed blood‑cell recovery after long‑frozen cord‑blood transplant
This trial tries sulforaphane to see if it helps adults with high‑risk AML, ALL, or MDS recover blood cells faster after receiving cord blood units frozen for 10 years or more.
-
Daratumumab versus rituximab for adult primary immune thrombocytopenia
This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.
-
Daratumumab for refractory aplastic anemia in adults
This trial tests whether daratumumab can be safely given and help people with refractory aplastic anemia see a benefit.
-
Mobile technology–assisted maintenance therapy for children with acute lymphoblastic leukemia
This study will try a mobile phone app with reminders and telemedicine scheduling to help children with acute lymphoblastic leukemia keep their medication dosing in the target range.
-
Obinutuzumab plus zanubrutinib and lenalidomide as first treatment for mantle cell lymphoma
This trial will test whether a combination of obinutuzumab, zanubrutinib, and lenalidomide (with CAR‑T offered for high‑risk patients) works as a first‑line option for people newly diagnosed with mantle cell lymphoma.
-
BAFF-R CAR-T therapy for relapsed or refractory BAFF-R–positive B-cell lymphoma
This trial will test whether a BAFF‑R–targeted CAR‑T cell therapy is safe and can help adults with relapsed or refractory BAFF‑R–positive B‑cell lymphomas (such as DLBCL, CLL, FL, MCL, or WM).
-
Nursing home and home-care cohort for older adults
This project will follow people aged 60 and older in nursing homes and in home care to see if a new elderly care complex model leads to better health and more active-health awareness than home-based care.
-
Dual-target CAR-T therapy (CAR19-BCMA) for relapsed or refractory multiple myeloma
This trial will test whether a dual-target CAR-T cell therapy that targets CD19 and BCMA is safe and tolerable for adults with relapsed or refractory multiple myeloma.
-
CD5 CAR-T therapy for relapsed or refractory CD5-positive blood cancers
This study will try a CD5 CAR-T cell therapy in people whose CD5-positive blood cancers have come back or not responded to prior treatments.
-
Rituximab plus anti‑CD38 antibody versus rituximab alone for primary immune thrombocytopenia
This trial will test whether adding an anti‑CD38 antibody (daratumumab) to rituximab helps adults with primary ITP who did not respond to or relapsed after steroid treatment.
-
Umbilical cord mesenchymal stem cell treatment for persistent cytopenia after CAR‑T
This trial will try giving umbilical cord blood–derived mesenchymal stem cells to adults with persistent severe low blood counts three weeks after CAR‑T therapy to see if their blood counts recover and to check safety.
-
Metformin to see if it lowers DNMT3A CH in acute leukemia remission
This study tests whether metformin can reduce DNMT3A R882 clonal hematopoiesis in people with acute leukemia who are in remission.
-
Liposomal Amphotericin B plus Posaconazole or Isavuconazole for Mucormycosis in Blood Cancers
This study will test whether combining IV liposomal amphotericin B with posaconazole or isavuconazole can treat mucormycosis in adults with blood cancers.
-
BCMA CAR-T with or without autologous stem cell transplant for young multiple myeloma patients
This will test whether BCMA-directed CAR-T cell therapy, given with or without autologous stem cell transplant (ASCT), helps young women (ages 18–55) with newly diagnosed multiple myeloma.
-
Methylene blue added to treat CAR‑T–related CRS and ICANS
This study will test whether giving methylene blue alongside standard care helps people who develop CRS or ICANS after CAR‑T cell or bispecific antibody therapy.
-
ZGR: zanubrutinib plus obinutuzumab and lenalidomide for newly diagnosed splenic B‑cell lymphoma with prominent nucleoli
This trial tries the ZGR combination (zanubrutinib, obinutuzumab, and lenalidomide) as first‑line treatment for people with newly diagnosed SBLPN to see if it is effective and well tolerated.
-
supCD7 CAR-T for relapsed or refractory CD7-positive T-cell leukemia/lymphoma and AML
This treatment will try supCD7 CAR‑T cells to see if they help adults whose CD7‑positive T‑cell leukemia/lymphoma or AML has come back or not responded to prior therapy.
-
Treatment plan for newly diagnosed pediatric Philadelphia chromosome–positive B‑cell acute lymphoblastic leukemia
This Phase 3 effort tests a chemotherapy‑light approach using olverembatinib together with blinatumomab and intermittent venetoclax to see if children and adolescents newly diagnosed with Ph+ B‑ALL can be cured with less toxicity.
-
Low-dose BCMA/CD3 (CM336) treatment for newly diagnosed AL (light-chain) amyloidosis
This trial will try a low-dose BCMA/CD3 bispecific antibody (CM336) in adults newly diagnosed with systemic light-chain (AL) amyloidosis to see if it is safe and lowers abnormal light-chain levels and helps organ function.
-
Treating breakthrough invasive fungal infections in blood cancer patients with liposomal amphotericin B versus isavuconazole/posaconazole
This project will test whether liposomal amphotericin B or isavuconazole/posaconazole works better and is safer for adults with blood cancers who develop breakthrough invasive fungal infections after antifungal prophylaxis.
-
Venetoclax plus Azacitidine versus Daunorubicin/Idarubicin plus Cytarabine induction for fit older adults with AML
This trial will test whether Venetoclax plus Azacitidine works as well as standard daunorubicin or idarubicin plus cytarabine induction in fit adults aged 55–75 with acute myeloid leukemia.
-
Post-remission treatments for MRD-positive adult AML
This study will try different drug regimens to see if they help people aged 14 and older with AML who are in remission but still MRD-positive stay relapse-free and live longer.
-
Autologous stem cell infusion for prolonged low blood counts after CAR-T therapy
This will try giving adults who had CAR-T therapy for multiple myeloma an infusion of their own stem cells to treat prolonged low blood counts.
-
Donor-derived γδ T cell therapy for MRD-positive AML after stem-cell transplant
This trial tests whether giving donor-derived γδ T cells can help adults with MRD-positive AML after an allogeneic stem-cell transplant.
-
Radiation plus BCMA/CD3 bispecific antibody (CM336) for solitary bone plasmacytoma with mild marrow involvement
This will test whether adding the BCMA/CD3 bispecific antibody CM336 after radiotherapy can clear remaining cancer cells and lower the chance of progression in adults with solitary bone plasmacytoma and small amounts of bone marrow involvement.
-
BCMA/CD3 bispecific antibody therapy for POEMS syndrome
This trial tests CM336, a BCMA/CD3 bispecific antibody, in adults with POEMS syndrome to see if it is safe and can help the condition.
-
Universal CD7 CAR-T therapy for relapsed or refractory CD7-positive blood cancers
This trial will test whether universal CD7 CAR-T cells can safely reduce disease in adults whose CD7-positive AML or T-ALL/LBL has relapsed or stopped responding to prior treatments.
-
Autologous stem‑cell transplant plus BCMA CAR‑T for ultra‑high‑risk multiple myeloma
This test combines an autologous stem‑cell transplant with BCMA CAR‑T therapy to see if it helps adults (18–70) with ultra‑high‑risk multiple myeloma who are eligible for transplant.
-
CD180 CAR-T for relapsed or refractory CD180-positive blood cancers
This trial will test whether an intravenous CD180 CAR‑T cell therapy can help adults with relapsed or refractory CD180‑positive AML or B‑ALL/LBL.
-
MRD‑guided BCMA CAR-T with optional GPRC5D/CD3 BiTE consolidation for transplant‑ineligible newly diagnosed multiple myeloma
This trial will try MRD‑guided immunotherapy using BCMA CAR‑T for adults newly diagnosed with multiple myeloma who cannot have a transplant, adding a GPRC5D/CD3 bispecific antibody for those at very high risk.
-
Autologous stem cell transplant combined with CD7 CAR‑T for CD7‑positive T‑cell lymphoma
This will test whether giving a patient's own stem cell transplant together with CD7‑targeted CAR‑T cells can safely and better treat adults with CD7‑positive T‑cell lymphoma.
-
High‑dose transplant with BCMA CAR‑T followed by GPRC5D/CD3 bispecific antibody maintenance for ultra‑high‑risk newly diagnosed multiple myeloma
This trial will test whether combining autologous stem‑cell transplant, BCMA CAR‑T cells, and GPRC5D/CD3 bispecific antibody maintenance helps people under 70 with newly diagnosed ultra‑high‑risk multiple myeloma.
-
Autologous transplant with BCMA CAR-T followed by GPRC5D/CD3 bispecific antibody maintenance for transplant‑eligible primary plasma cell leukemia
This plan will try combining high‑dose autologous stem cell transplant and BCMA CAR‑T followed by GPRC5D/CD3 bispecific antibody maintenance to see if it improves remission and disease control in transplant‑eligible primary plasma cell leukemia.
-
Siltuximab treatment for CRS and ICANS after CAR‑T in multiple myeloma
We will test whether siltuximab helps adults with multiple myeloma who develop CRS or ICANS after receiving CAR‑T therapy.
-
Romiplostim N01 to treat chemotherapy-related low platelets
This will test whether Romiplostim N01 can raise platelet counts in adults whose platelets remain very low after chemotherapy and did not respond to other platelet-boosting drugs.
-
Anti-CD38 antibody treatment for elderly people with primary immune thrombocytopenia
This trial will try the anti-CD38 antibody daratumumab to raise platelet counts in people aged 60 and older with primary ITP who have not responded to multiple treatments.
-
National longitudinal cohort for large granular lymphocytic leukemia (LGLL)
This project will collect past and ongoing medical data to test what factors affect diagnosis, treatments, and outcomes for people in China with T-LGL or NK-LGL leukemia.
-
National longitudinal cohort of autoimmune hemolytic anemia in China
This project will follow people with warm, cold, or mixed autoimmune hemolytic anemia treated at a major Tianjin hematology center to see what treatments they receive and how well they do over time.
-
Lower-dose immunosuppression plus hetrombopag for severe aplastic anemia in people 65 and older
This study tests whether a lower-dose immunosuppressive regimen combined with hetrombopag can improve blood counts and safety for people aged 65 and older with severe or very severe aplastic anemia.
-
Treatment for relapsed or refractory aggressive B-cell lymphoma using bispecific antibodies and CAR-T therapy
This study is testing a new treatment for patients with aggressive B-cell lymphoma that combines a special antibody and CAR-T therapy to see if it helps them feel better and live longer.
-
Romiplostim combined with glucocorticoids for treating newly diagnosed adult ITP
This study is testing if a new treatment combining romiplostim and glucocorticoids can help adults newly diagnosed with immune thrombocytopenia feel better compared to just using glucocorticoids alone.
-
Marstacimab experiences in adolescents and adults with hemophilia
This registry will collect experiences from adolescents and adults with hemophilia who are receiving marstacimab to see if they prefer subcutaneous injections and to track treatment burden and bleeding rates.
-
CT0596 CAR-T treatment for plasma cell leukemia
The study will try CT0596 CAR‑T cell therapy in adults with plasma cell leukemia to see if it is safe and can shrink the disease.
-
CAR T-cell therapy for autoimmune diseases
This study is testing a new CAR T-cell therapy to see if it can help people with tough autoimmune diseases like lupus and systemic sclerosis feel better.
-
Impact of Aplastic Anemia on Reproductive and Mental Health
This study looks at how aplastic anemia and its treatments affect the reproductive and mental health of young adults aged 18-40.
-
Evaluating brain function and psychological effects of cell therapy in autoimmune hemolytic anemia
This study is testing how CAR T-cell therapy affects thinking and mental health in people with autoimmune hemolytic anemia to help improve their treatment and quality of life.
-
Immediate versus bridging allogeneic stem cell transplantation for higher-risk myelodysplastic syndrome
This trial tries to see if getting an allogeneic stem cell transplant right away or after short bridging therapy works better for adults with higher-risk myelodysplastic syndrome.
-
Newly diagnosed low‑risk pediatric B‑cell ALL treatment with short blinatumomab courses
This protocol will try giving two short 14‑day courses of blinatumomab early and during consolidation for children with newly diagnosed low‑risk B‑cell ALL to allow less intensive later chemotherapy when deep MRD negativity is achieved.
-
Preventing severe acute graft‑versus‑host disease in high‑risk adults with an anti‑CD25 antibody
This trial will try a recombinant humanized anti‑CD25 antibody to prevent severe aGVHD in adults the daGOAT model flags as intermediate‑to‑high risk after allogeneic stem cell transplant.
-
BCMA CAR-T treatment for high-risk multiple myeloma patients
This study is testing a new CAR-T cell therapy for people with high-risk multiple myeloma to see if it can help them after they’ve tried other treatments.
-
Autologous CAR-T therapy for a functional cure of HIV-1/AIDS
This trial will test whether a patient's own CAR-T immune cells can help achieve long-term control of HIV in adults on stable antiviral therapy.
-
CLL1 and CD38 dual-target CAR-T treatment for relapsed or refractory acute myeloid leukemia
This trial will test an infusion of CLL1 and CD38 dual-target CAR-T cells in adults with relapsed or refractory acute myeloid leukemia to see if it is safe and shows early signs of benefit.
-
New treatment approach for children newly diagnosed with T‑cell acute lymphoblastic leukemia using dasatinib, venetoclax, and homoharringtonine
This study will try adding dasatinib, venetoclax, and homoharringtonine to standard chemotherapy for children and adolescents newly diagnosed with T‑cell acute lymphoblastic leukemia to see if it increases deep (MRD‑negative) remissions and lowers relapse.
-
Treatment for primary immune thrombocytopenia using Anti-CD38 antibody
This study is testing a new treatment using an antibody called Daratumumab to see if it can help people with hard-to-treat immune thrombocytopenia improve their platelet counts and reduce bleeding risks.
-
Evaluating Herombopag for treating elderly patients with ITP
This study is testing if the medication Herombopag can help older patients with Immune Thrombocytopenic Purpura (ITP) improve their platelet counts and overall health.
-
Exploring CM336 for treating immune thrombocytopenia
This study is testing a new treatment called CM336 to see if it can help adults with hard-to-treat immune thrombocytopenia feel better and manage their low platelet counts.
-
Aponermin treatment before CAR-T therapy for multiple myeloma patients with extramedullary disease
This study is testing if aponermin treatment can help multiple myeloma patients with extra tumors feel better before they receive CAR-T therapy.
-
Comparing BCMA CAR-T therapy to stem cell transplant for multiple myeloma
This study is testing if a new CAR-T therapy for multiple myeloma works just as well as a stem cell transplant for patients who are eligible for both treatments.
-
Using umbilical cord blood cells to treat poor graft function after stem cell transplantation
This study is testing if umbilical cord blood cells can help people with poor graft function after a stem cell transplant feel better and improve their health.
-
Combining avapritinib, azacitidine, and venetoclax for treating relapsed AML after stem cell transplant
This study is testing a new combination of three medications to see if they can help people with relapsed acute myeloid leukemia feel better after a stem cell transplant.
-
NAD (nicotinamide adenine dinucleotide) for immune thrombocytopenia (ITP)
This trial will try NAD (nicotinamide adenine dinucleotide) to raise platelet counts in adults with persistent or relapsed ITP who did not respond to steroids and at least one second-line therapy.
-
New treatment options for children with high-risk B-cell leukemia
This study is testing two different treatment options for children with high-risk B-cell leukemia to see which one helps them get better and live longer.
-
Combination treatment for blast phase CML using olverembatinib, venetoclax, and azacitidine
This study is testing a new combination of three medications to see if it can help people aged 15 and older with blast phase chronic myeloid leukemia feel better and improve their treatment options.
-
BCMA/CD3 BiTE therapy for high-risk smoldering multiple myeloma
A BCMA/CD3 BiTE called CM-336 is being tested to see if it can safely and effectively help people with high-risk smoldering multiple myeloma.
-
Comparing standard-dose and intermediate-dose cytarabine for treating acute myeloid leukemia with RUNX1-RUNX1T1 fusion
This study is testing if using a higher dose of cytarabine can help adults with acute myeloid leukemia who have a specific gene fusion feel better and achieve remission compared to the standard dose.
-
Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas
This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.
-
CD19 CAR-T for relapsed or treatment-resistant autoimmune diseases
This trial will test whether a patient's own CD19 CAR-T cells can help adults with relapsed or refractory autoimmune diseases like SLE, systemic sclerosis, ANCA-associated vasculitis, inflammatory myopathies, or Sjögren's syndrome.
-
Combining Venetoclax with Intensive Chemotherapy for Acute Myeloid Leukemia
This study is testing if adding Venetoclax to strong chemotherapy helps adults with Acute Myeloid Leukemia feel better and which genetic types benefit the most from this treatment.
-
Venetoclax with ivosidenib and azacitidine for newly diagnosed AML with an IDH1 mutation
This treatment tests whether combining venetoclax, ivosidenib, and azacitidine helps people newly diagnosed with AML that has an IDH1 mutation.
-
Combining a new cell therapy with stem cell transplantation for leukemia patients in remission
This study is testing a new cell therapy combined with stem cell transplantation to see if it can help teenagers and adults with a type of leukemia who are in remission but still have some cancer cells left.
-
Combining stem cell transplantation with CD19-CART for treating high-risk leukemia in adults
This study is testing a new treatment that combines stem cell transplant with a special type of immune therapy to see if it helps adults with high-risk leukemia feel better and stay in remission.
-
Longitudinal study of CAR-T cell therapy in patients with blood cancers
This study looks at how well CAR-T cell therapy works for Chinese patients with blood cancers by gathering information from those who have already received this treatment.
-
Evaluating R-CMOP treatment for newly diagnosed diffuse large B-cell lymphoma
This study is testing a new combination treatment for people with newly diagnosed diffuse large B-cell lymphoma to see if it is safe and effective.
-
Efficacy of a triple drug regimen for newly diagnosed AML patients with FLT3 mutation
This study is testing a new combination of three drugs to see if it helps newly diagnosed acute myeloid leukemia patients with FLT3 mutations respond better to treatment.
-
Thalidomide treatment for symptomatic large granular lymphocytic leukemia
This study is testing if thalidomide can help people with symptomatic large granular lymphocytic leukemia feel better by seeing how well it works on its own.
-
Using PI3K inhibitors to treat relapsed indolent T/NK-cell lymphomas
This study is testing if two new oral medications can help people with relapsed indolent T/NK-cell lymphomas feel better and improve their treatment options.
-
Intermediate-dose treatment for CEBPA double-mutated AML
This study is testing a new intermediate-dose treatment for people with CEBPA double-mutated acute myeloid leukemia to see if it works better than the standard treatment.
-
Linperlisib with immunochemotherapy for relapsed large B-cell lymphoma
This study is testing if adding Linperlisib to standard immunochemotherapy helps people with relapsed large B-cell lymphoma feel better and have more treatment options.
-
Combining chemotherapy with CAR-T cell therapy for newly diagnosed adult patients with Philadelphia Chromosome Negative ALL
This study is testing if combining CAR-T cell therapy with chemotherapy can help adults newly diagnosed with Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia feel better and live longer.
-
Combining CAR-T therapy with chemotherapy for newly diagnosed Ph+ acute lymphoblastic leukemia
This study is testing a new treatment that combines CAR-T therapy with chemotherapy to see if it can help adults with newly diagnosed Ph+ acute lymphoblastic leukemia feel better and live longer.
-
Treatment for relapse of acute myeloid leukemia after stem cell transplant
This study is testing a new treatment combining chemotherapy and donor immune cells for people who have relapsed acute myeloid leukemia after a stem cell transplant to see if it helps them recover safely.
-
Combining low-dose chemotherapy with immuno-targeted drugs for elderly patients with Ph-negative B-ALL
This study is testing a new treatment that combines low-dose chemotherapy with targeted drugs to see if it can help older patients with a specific type of leukemia feel better and stay in remission longer.
-
Combination treatment for newly diagnosed acute myeloid leukemia
This study is testing a new combination treatment for adults with newly diagnosed acute myeloid leukemia who can't have standard chemotherapy to see if it can help them safely and effectively.
-
CAR T cell therapy for children with relapsed B-cell leukemia
This study is testing a new CAR T cell therapy to see if it can help children aged 3 to 18 with relapsed or hard-to-treat B-cell leukemia.
-
Using avatrombopag to treat pediatric immune thrombocytopenia
This study is testing if a new medication called avatrombopag can help children aged 6 to 18 with immune thrombocytopenia who didn't do well on their previous treatment.
-
Exploring new treatment options for refractory or relapsed acute myeloid leukemia
This study is testing different treatment options for people with stubborn or returning acute myeloid leukemia to see which ones work best for them.
-
Using Rituximab to treat severe aplastic anemia with platelet transfusion issues
This study is testing if rituximab can help people with severe aplastic anemia who have trouble getting enough platelets from transfusions.
-
Treatment for patients with aggressive non-Hodgkin's lymphoma
This study is testing a new combination treatment for people with aggressive non-Hodgkin's lymphoma to see if it helps them feel better and improve their health.
-
Evaluating NGGT003 for treating Hemophilia A
This study is testing a new treatment called NGGT003 to see if it can safely help men with hemophilia A by allowing their bodies to produce a missing protein.
-
Assessing and Modulating Immune Recovery After Transplant
This study is testing whether a new way to track and support patients after a specific type of stem cell transplant can help them recover their immune system better.
-
Treatment for pediatric immune thrombocytopenia using Anti-CD38 antibody
This study is testing a new antibody treatment for children with immune thrombocytopenia who haven't had success with other therapies to see if it can help improve their condition.
-
Treatment for newly diagnosed double-hit multiple myeloma
This study is testing a new treatment plan for people with newly diagnosed double-hit multiple myeloma to see if it helps them get better and stay in remission after a stem cell transplant.
-
Long-term observation of children with primary immune thrombocytopenia
This study looks at how children with primary immune thrombocytopenia are treated and what their long-term health outcomes are in order to better understand the condition.
-
Identifying blood markers for early diagnosis of transplant-related complications
This study is trying to find blood markers that can help doctors spot early signs of a serious complication called TA-TMA in patients who have had a stem cell transplant.
-
Using Obinutuzumab to treat pediatric immune thrombocytopenia
This study is testing if Obinutuzumab can help teenagers with immune thrombocytopenia who haven't responded well to other treatments.
-
Comparing growth and development in children with beta-thalassemia after gene therapy
This study looks at how gene therapy affects the growth and development of children with beta-thalassemia compared to those getting regular treatments and healthy kids.
-
Combination therapy for patients with primary plasma cell leukemia who cannot undergo transplant
This study is testing a new combination treatment for patients with primary plasma cell leukemia who can't have a transplant to see if it helps manage their disease better.
-
New combination therapy for untreated nodal TFH cell lymphoma
This study is testing a new combination treatment for people with untreated angioimmunoblastic T-cell lymphoma to see if it helps them respond better to therapy.
-
Treatment for Hemophilia A in Adolescents and Adults with High Titer Inhibitor
This study is testing if a new treatment for hemophilia A, using a drug called SCT800 alone or with another drug called Daratumumab, can help teenagers and adults with high titer inhibitors feel better and have fewer relapses.
-
Combining pegylated interferon α-2b with ruxolitinib for treating resistant polycythemia vera
This study is testing if combining two medications, pegylated interferon α-2b and ruxolitinib, can help people with polycythemia vera who haven't responded well to other treatments feel better.
-
Using a CD38 antibody with corticosteroids to treat acquired hemophilia A
This study is testing if a combination of a new antibody treatment and steroids can help people with acquired hemophilia A stop bleeding and stay healthy.
-
Combining obinutuzumab and lenalidomide for treating relapsed follicular lymphoma
This study is testing if combining obinutuzumab and lenalidomide can help people in China with relapsed follicular lymphoma feel better and live longer, while keeping their current treatment plans.
-
Combining obinutuzumab and lenalidomide for treating relapsed marginal zone lymphoma
This study is testing a combination of two medications, obinutuzumab and lenalidomide, to see if they can help people with relapsed marginal zone lymphoma feel better.
-
Gene therapy for teenagers with Hemophilia B
This study is testing a new gene therapy for teenagers with Hemophilia B to see if a single treatment can help their bodies produce more of the factor IX protein they need.
-
Combining a pediatric treatment approach with Venetoclax for young and adult patients with a specific type of leukemia
This study is testing a new treatment plan that combines a pediatric approach with Venetoclax to see if it helps teenagers and adults with a specific type of leukemia achieve better recovery and reduce the chance of relapse.
-
Evaluating ZS801 for treating Hemophilia B in adults
This study is testing a new treatment called ZS801 to see if it can safely help adults with hemophilia B improve their blood-clotting factor levels.
-
Using stem cell transplantation with C-CAR088 to treat ultra high-risk multiple myeloma
This study is testing a new treatment combining stem cell transplantation and a special CAR-T cell therapy to see if it can help people with ultra high-risk multiple myeloma who haven't responded well to other treatments.
-
Evaluating ZS801 for treating Hemophilia B in Chinese patients
This study is testing a new treatment called ZS801 to see if it can help men with Hemophilia B manage their bleeding better.
-
Olverembatinib plus APG-2575 for children with relapsed or refractory Philadelphia-positive ALL
This study tests whether a combination of olverembatinib and APG-2575, with dexamethasone, is safe and potentially effective in children with relapsed or refractory Ph+ ALL who have already tried other TKIs.
-
Gene therapy for treating Hemophilia A
This study is testing a new gene therapy to see if a single injection can help men with Hemophilia A increase their factor VIII levels and reduce bleeding.
-
Using Mecapegfilgrastim with chemotherapy to mobilize stem cells in blood for cancer treatment
This study is testing if giving mecapegfilgrastim after chemotherapy can help patients with multiple myeloma or lymphoma collect enough stem cells from their blood for a transplant.
-
Using Herombopag to treat low platelet counts from chemotherapy
This study is testing if a new medication called Herombopag can help increase low platelet counts in patients who have not responded well to other treatments after chemotherapy.
-
Using zanubrutinib to treat immune thrombocytopenia
This study tests if zanubrutinib can help people with immune thrombocytopenia who haven't had success with other treatments.
-
Using zanubrutinib to treat antiphospholipid syndrome with low platelet counts
This study is testing if zanubrutinib can help people with antiphospholipid syndrome and low platelet counts who haven't found relief with other treatments.
-
Using avatrombopag to treat adult immune thrombocytopenia with autoantibodies
This study is testing if avatrombopag can help adults with immune thrombocytopenia who have autoantibodies and haven't had success with other treatments.
-
Gene therapy for hemophilia A in adults
This study is testing a new gene therapy to see if it can safely help adults with hemophilia A who have very low levels of a crucial clotting factor.
-
Comparing Chlorpheniramine and placebo to prevent allergic reactions during blood transfusions
This study is testing if taking chlorpheniramine before a blood transfusion can help prevent allergic reactions in adults with blood disorders.
-
Long-term study of blood diseases in patients in China
This study is trying to gather detailed information from patients in China with blood diseases like leukemia and multiple myeloma to better understand how these conditions affect their lives and treatment options.
-
Eltrombopag treatment for low platelet counts caused by chemotherapy
This study is testing if eltrombopag can help increase low platelet counts in patients who haven't responded to other treatments after chemotherapy.
-
Eltrombopag with rituximab versus eltrombopag alone for adults with ITP
This study tests whether adding a single rituximab infusion to daily eltrombopag helps adults with previously treated ITP who still have low platelets.
-
ALL-style chemotherapy for people with acute leukemia of ambiguous lineage.
This trial will try ALL-style chemotherapy (including vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone) in people aged 14 and older with acute leukemia of ambiguous lineage and may offer stem-cell transplant after remission.
-
Evaluating a new treatment approach for chronic lymphocytic leukemia
This study is testing a new treatment plan that combines two established therapies with ibrutinib to see if it helps people with chronic lymphocytic leukemia who haven't had treatment before.
Quick answers
How many clinical trials run by Institute of Hematology & Blood Diseases Hospital, China are recruiting right now?
150, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (150 trials), Hong Kong (4 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 66, Phase 1/2: 14, Phase 1: 13, Early Phase 1: 8. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.